A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Completed
UroGen Pharma Ltd.
Phase 2
The study is investigating the efficacy and safety of UroGen's UGN-102 to treat patients with
Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.
A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Recruiting
UroGen Pharma Ltd.
Phase 3
This is a global, randomized, controlled, open-label Phase 3 study designed to assess the
long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or
without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the
treatment of patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG
IR NMIBC).
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)
Recruiting
UroGen Pharma Ltd.
Phase 3
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to
instillation in a clinical setting, which might mitigate some of the challenges in the
patient experience (logistical, expense, and comfort) when receiving treatment for low-grade
non-muscle-invasive bladder cancer at intermediate risk of recurrence (LG IR NMIBC).
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Recruiting
UroGen Pharma Ltd.
Phase 3
This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and
safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate
risk non-muscle-invasive bladder cancer (LG IR NMIBC).
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
RECRUITING
UroGen Pharma Ltd.
PHASE3
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
